Can-Fite BioPharma Ltd. (NYSE: CANF) moved higher Friday. The Israel-based company, a clinical-stage biotechnology concern developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Japan Patent Office has allowed Japanese Patent Application No. 2025-049941, a divisional application of JP 2023-078136, titled "An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect."
The allowed patent covers the use of A3 adenosine receptor (A3AR) agonists, including the Company's lead drug candidate Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders.
The Japanese patent allowance represents another significant milestone in Can-Fite's expanding global intellectual property portfolio covering Namodenoson's anti-obesity activity. The Company has already secured patent protection for this technology in major jurisdictions including the United States, Canada, Australia and Israel, further strengthening its worldwide exclusivity strategy for this promising therapeutic indication.
The growing patent estate is supported by scientific evidence recently published in the peer-reviewed International Journal of Obesity, demonstrating Namodenoson's anti-obesity activity and providing independent scientific validation for its novel mechanism of action.
The global obesity therapeutics market continues to experience rapid expansion, driven by increasing disease prevalence and the commercial success of GLP-1 receptor agonists.
CANF shares kicked off Friday higher 52 cents, or 17.9%, to $3.46.
